Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cell culture–based flu vaccine maintains immunogenicity

Key clinical point: A mostly egg-free flu vaccine released commercially in 2018-2019 induced similar serologic responses as a fully egg-grown vaccine.

Major finding: Seropositivity after 28 days to the B Victoria lineage influenza was 76% with Flucelvax and 79% with Fluzone by a hemagglutination inhibition assay.

Study details: A single-center, randomized U.S. study with 148 evaluable individuals aged 4-20 years old.

Disclosures: The study received no commercial funding but received free Fluzone vaccine from Sanofi Pasteur. Dr. Zimmerman had no disclosures.

Citation:

Zimmerman RK. ID Week 2019.